Terms: = Liver cancer AND SRSF2, Q01130, 6427, SFRS2 AND Treatment
4 results:
1. HBV Enhances Sorafenib Resistance in Hepatocellular Carcinoma by Reducing Ferroptosis via srsf2-Mediated Abnormal PCLAF Splicing.
Liu L; Lv Z; Wang M; Zhang D; Liu D; Zhu F
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834680
[TBL] [Abstract] [Full Text] [Related]
2. Systemic Mastocytosis: Advances in Diagnosis and Current Management.
Pullarkat ST; Wu W; Pullarkat V
Cancer Treat Res; 2021; 181():167-178. PubMed ID: 34626361
[TBL] [Abstract] [Full Text] [Related]
3. Momelotinib therapy for myelofibrosis: a 7-year follow-up.
Tefferi A; Barraco D; Lasho TL; Shah S; Begna KH; Al-Kali A; Hogan WJ; Litzow MR; Hanson CA; Ketterling RP; Gangat N; Pardanani A
Blood Cancer J; 2018 Mar; 8(3):29. PubMed ID: 29515114
[TBL] [Abstract] [Full Text] [Related]
4. DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of srsf2 expression.
Ma K; He Y; Zhang H; Fei Q; Niu D; Wang D; Ding X; Xu H; Chen X; Zhu J
J Biol Chem; 2012 Feb; 287(8):5639-49. PubMed ID: 22117060
[TBL] [Abstract] [Full Text] [Related]
